Covered recipient · General Payments record
JOHN V HEYMACH
Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2024 · Entire year
$160,752.57
111 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2024 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $111,868.85 | 34 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $27,300.70 | 16 |
| Travel and Lodging | $18,835.91 | 19 |
| Food and Beverage | $2,747.11 | 42 |
By paying entity
PY2024 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | $30,242.89 | 18 |
| BioNTech SE | $25,615.29 | 10 |
| Regeneron Pharmaceuticals, Inc. | $20,604.50 | 22 |
| OPKO Pharmaceuticals, LLC | $20,000.00 | 2 |
| Janssen Biotech, Inc. | $13,053.06 | 16 |
| Boehringer Ingelheim International GmbH | $9,558.50 | 13 |
| Takeda Pharmaceuticals U.S.A., Inc. | $7,247.34 | 3 |
| EMD Serono Research & Development Institute, Inc. | $6,588.90 | 1 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $6,537.64 | 4 |
| GlaxoSmithKline, LLC. | $4,831.50 | 6 |
| PFIZER INC. | $4,510.66 | 4 |
| E.R. Squibb & Sons, L.L.C. | $3,912.76 | 3 |
| ABBVIE INC. | $3,475.00 | 2 |
| EMD Serono, Inc. | $3,000.00 | 1 |
| Daiichi Sankyo Inc. | $1,250.00 | 1 |
| AstraZeneca UK Limited | $160.00 | 2 |
| Genentech USA, Inc. | $77.91 | 1 |
| JAZZ PHARMACEUTICALS INC. | $57.62 | 1 |
| Mirati Therapeutics, Inc. | $29.00 | 1 |
Page 3 of 3; records 101–111 of 111 matching records. This page contains 11 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
JOHN V HEYMACH
NPI 1417056565 · CMS profile ID 245762
Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology
HOUSTON, TX
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 3 of 3; records 101–111 of 111 matching records. This page contains 11 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1417056565?year=2024&recipient=provider&page=3#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- JOHN V HEYMACH, NPI 1417056565, CMS profile ID 245762. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–111 of 111 matching records. This page contains 11 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1417056565?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- APA 7
- IndustryPayments. (2026). JOHN V HEYMACH, NPI 1417056565, CMS profile ID 245762. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–111 of 111 matching records. This page contains 11 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1417056565?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- Bluebook
- JOHN V HEYMACH, NPI 1417056565, CMS profile ID 245762, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–111 of 111 matching records. This page contains 11 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1417056565?year=2024&recipient=provider&page=3#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2024
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30
111 matching records · $160,752.57 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 101–111 of 111.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Janssen Biotech, Inc. | $81.35 | 01/19/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1078725981 | CMS |
| Janssen Biotech, Inc. | $173.35 | 01/18/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1078722529 | CMS |
| Janssen Biotech, Inc. | $63.87 | 01/18/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1078724640 | CMS |
| Janssen Biotech, Inc. | $181.35 | 01/18/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1078730323 | CMS |
| BioNTech SE | $3,603.20 | 01/16/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1150660510 | CMS |
| Janssen Biotech, Inc. | $816.43 | 01/12/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1078724944 | CMS |
| Janssen Biotech, Inc. | $700.00 | 01/12/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1078730094 | CMS |
| Boehringer Ingelheim International GmbH | $217.24 | 01/11/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1117999397 | CMS |
| Boehringer Ingelheim International GmbH | $461.77 | 01/11/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1117999407 | CMS |
| Boehringer Ingelheim International GmbH | $505.55 | 01/11/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1117999411 | CMS |
| Boehringer Ingelheim International GmbH | $556.10 | 01/11/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1117999417 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $3,205,094.68 | 86 |
| PY2024 | Principal investigator | $1,248,647.12 | 9 |
| PY2023 | Recipient | $543.79 | 1 |
| PY2023 | Principal investigator | $1,866,391.56 | 16 |
| PY2022 | Principal investigator | $1,123,526.96 | 7 |
| PY2021 | Recipient | $1,386.68 | 2 |
| PY2021 | Principal investigator | $783,527.48 | 7 |
| PY2020 | Principal investigator | $1,097,038.73 | 8 |
| PY2019 | Principal investigator | $1,829,138.77 | 8 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
86 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $298,840.32 | 12/25/2025 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220810122 |
| Principal investigator 1 | Boehringer Ingelheim Espana S.A. | $39.85 | 12/01/2025 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220577944 |
| Principal investigator 1 | Boehringer Ingelheim Espana S.A. | $19.98 | 12/01/2025 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220577946 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $368,373.84 | 11/30/2025 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220997704 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,666.19 | 11/13/2025 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220810120 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,588.89 | 11/12/2025 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220810116 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,144.99 | 11/12/2025 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220810118 |
| Principal investigator 1 | Boehringer Ingelheim Espana S.A. | $39.85 | 11/01/2025 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220577940 |
| Principal investigator 1 | Boehringer Ingelheim Espana S.A. | $39.85 | 11/01/2025 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220577942 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $276,280.38 | 10/31/2025 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220997700 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $621.85 | 10/30/2025 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220810114 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $146.50 | 10/27/2025 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220997706 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $99.90 | 10/27/2025 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220997708 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $888.25 | 10/23/2025 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220810112 |
| Principal investigator 1 | Boehringer Ingelheim Espana S.A. | $39.85 | 10/01/2025 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220577938 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $378,606.44 | 09/30/2025 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220997702 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $561.19 | 09/25/2025 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220810110 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $703.20 | 09/24/2025 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220997690 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $174.90 | 09/24/2025 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220997692 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $179.82 | 09/24/2025 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220997694 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $3.60 | 09/24/2025 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220997696 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $931.50 | 09/23/2025 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220810108 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $602.38 | 09/11/2025 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220810104 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $752.00 | 09/11/2025 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220810106 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $901.81 | 09/05/2025 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220810102 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $91,136.51 | 09/04/2025 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220810100 |
| Principal investigator 1 | Boehringer Ingelheim Espana S.A. | $39.85 | 09/01/2025 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220577936 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $378,606.44 | 08/31/2025 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220997698 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $996.20 | 08/26/2025 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220997682 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $303.16 | 08/26/2025 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220997684 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $519.48 | 08/26/2025 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220997686 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $15.60 | 08/26/2025 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220997688 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $907.31 | 08/21/2025 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220810098 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $968.04 | 08/20/2025 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220810088 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $363.64 | 08/20/2025 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220810090 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,367.98 | 08/20/2025 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220810092 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $897.60 | 08/20/2025 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220810094 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $975.61 | 08/20/2025 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220810096 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,176.44 | 08/12/2025 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220810086 |
| Principal investigator 1 | Boehringer Ingelheim Espana S.A. | $39.85 | 08/01/2025 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220577934 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $439.50 | 07/28/2025 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220997676 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $299.70 | 07/28/2025 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220997678 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $12.00 | 07/28/2025 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220997680 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,109.12 | 07/28/2025 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220810084 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $650.00 | 07/25/2025 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220810082 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $846.26 | 07/18/2025 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220810080 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $599.17 | 07/10/2025 | Covered Recipient Teaching Hospital Mayo Clinic Hospital | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220793969 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,311.23 | 07/10/2025 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220810078 |
| Principal investigator 1 | Boehringer Ingelheim Espana S.A. | $39.85 | 07/01/2025 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220577964 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,640.61 | 07/01/2025 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220810072 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $846.53 | 07/01/2025 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220810074 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $17,625.00 | 07/01/2025 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220810076 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $895.16 | 06/16/2025 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220810070 |
| Principal investigator 1 | Boehringer Ingelheim Espana S.A. | $39.85 | 06/01/2025 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220577962 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $42.41 | 06/01/2025 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase Ia/Ib, open-label, multicentre dose-escalation and expansion study to investigate the safety, pharmacokinetics and preliminary efficacy of BI 1823911 as a monotherapy and in combination with other anti-cancer therapies in patients with advanced or metastatic solid tumours expressing KRAS G12C mutation | No dispute reported | 06/30/2026 | 1220997652 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $119,378.66 | 05/30/2025 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | An Open-Label, Multi-Drug, Biomarker-Directed, Multi-Centre Phase II Umbrella Study in Patients with Non-Small Cell Lung Cancer, who Progressed on an anti-PD-1 PD-L1 Containing Therapy HUDSON | No dispute reported | 06/30/2026 | 1185549751 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $47.75 | 05/27/2025 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220997674 |
| Principal investigator 1 | Boehringer Ingelheim Espana S.A. | $39.85 | 05/01/2025 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220577960 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $42.41 | 05/01/2025 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase Ia/Ib, open-label, multicentre dose-escalation and expansion study to investigate the safety, pharmacokinetics and preliminary efficacy of BI 1823911 as a monotherapy and in combination with other anti-cancer therapies in patients with advanced or metastatic solid tumours expressing KRAS G12C mutation | No dispute reported | 06/30/2026 | 1220997650 |
| Principal investigator 1 | PUMA BIOTECHNOLOGY, INC. | $317,437.80 | 04/18/2025 | Non-covered Recipient Entity UNIVERSITY OF TEXAS, MD ANDERSON CANCER CTR | IST CCR-MDACC2-ALIS-001 (MDACC) DR. JOHNSON | No dispute reported | 06/30/2026 | 1251754236 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $126,727.89 | 04/14/2025 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220810068 |
| Principal investigator 1 | Boehringer Ingelheim Espana S.A. | $39.85 | 04/01/2025 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220577954 |
| Principal investigator 1 | Boehringer Ingelheim Espana S.A. | $107.76 | 04/01/2025 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220577956 |
| Principal investigator 1 | Boehringer Ingelheim Espana S.A. | $41.95 | 04/01/2025 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220577958 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $42.41 | 04/01/2025 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase Ia/Ib, open-label, multicentre dose-escalation and expansion study to investigate the safety, pharmacokinetics and preliminary efficacy of BI 1823911 as a monotherapy and in combination with other anti-cancer therapies in patients with advanced or metastatic solid tumours expressing KRAS G12C mutation | No dispute reported | 06/30/2026 | 1220997648 |
| Principal investigator 1 | AstraZeneca UK Limited | $135,000.00 | 03/27/2025 | Non-covered Recipient Entity UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER | Evaluation of PRMT5 inhibitors and their activity in combination with immunotherapy in CDKN2A MTAP deficient preclinical models of NSCLC | No dispute reported | 06/30/2026 | 1185549755 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $673.90 | 03/25/2025 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220997668 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $459.54 | 03/25/2025 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220997670 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $8.40 | 03/25/2025 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220997672 |
| Principal investigator 1 | Boehringer Ingelheim Espana S.A. | $39.85 | 03/01/2025 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220577952 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $42.41 | 03/01/2025 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase Ia/Ib, open-label, multicentre dose-escalation and expansion study to investigate the safety, pharmacokinetics and preliminary efficacy of BI 1823911 as a monotherapy and in combination with other anti-cancer therapies in patients with advanced or metastatic solid tumours expressing KRAS G12C mutation | No dispute reported | 06/30/2026 | 1220997646 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $468.80 | 02/25/2025 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220997662 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $319.68 | 02/25/2025 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220997664 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $12.00 | 02/25/2025 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220997666 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $380,624.91 | 02/13/2025 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | a phase 3b,randomized,multicenter,open label study to assess the efficacy of durvalumab plus tremelimumab versus pembrolizumab in combination with platinum based chemotherapy for first line treatment in mtastatic non small cell lung cancer patients with non squamous histology who have mutations and or co mutations in skt11,keap1,or kras triton | No dispute reported | 06/30/2026 | 1185549753 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,864.12 | 02/09/2025 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220810064 |
| Principal investigator 1 | Boehringer Ingelheim Espana S.A. | $39.85 | 02/01/2025 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220577950 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $42.41 | 02/01/2025 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase Ia/Ib, open-label, multicentre dose-escalation and expansion study to investigate the safety, pharmacokinetics and preliminary efficacy of BI 1823911 as a monotherapy and in combination with other anti-cancer therapies in patients with advanced or metastatic solid tumours expressing KRAS G12C mutation | No dispute reported | 06/30/2026 | 1220997644 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $1,465.00 | 01/27/2025 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220997654 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $46.64 | 01/27/2025 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220997656 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $839.16 | 01/27/2025 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220997658 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $22.80 | 01/27/2025 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220997660 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $340.84 | 01/24/2025 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220810066 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $277,838.35 | 01/03/2025 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | MDACC ALLIANCE - THORACIC | No dispute reported | 06/30/2026 | 1223272949 |
| Principal investigator 1 | Boehringer Ingelheim Espana S.A. | $39.85 | 01/01/2025 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220577948 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $42.41 | 01/01/2025 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase Ia/Ib, open-label, multicentre dose-escalation and expansion study to investigate the safety, pharmacokinetics and preliminary efficacy of BI 1823911 as a monotherapy and in combination with other anti-cancer therapies in patients with advanced or metastatic solid tumours expressing KRAS G12C mutation | No dispute reported | 06/30/2026 | 1220997642 |
Ownership and Investment Interests
One row per program year and measure, newest year first · the amount invested and the value of the interest are never added together
| Program year | Measure | Amount | Records |
|---|---|---|---|
| PY2020 | Amount invested | $0.00 | 1 |
| PY2020 | Value of interest | $93.69 | 1 |
| PY2019 | Amount invested | $0.00 | 1 |
| PY2019 | Value of interest | $221.46 | 1 |
Ownership and Investment Interests are a separate CMS dataset, shown here separately and never added to payments.
Ownership and investment interests are reported as the value of an interest held, not as a payment received. They are a different measure from the payment total on this page and are never combined with it.
Ownership and Investment Interests records
Ordering applied by this site (program year, newest first, then company) · record values are shown as CMS published them
2 records · PY2019–2020
| Program year | Company | Amount invested | Value of interest | Terms of interest | Interest held by | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| PY2020 | IGIP, LLC | $0.00 | $93.69 | 2020 royalty payment. | Physician Covered Recipient | No dispute reported | 06/30/2026 | 733499549 |
| PY2019 | IGIP, LLC | $0.00 | $221.46 | This amount is a 2% royalty payment for ownership in IGIP, LLC for 2019. | Physician Covered Recipient | No dispute reported | 06/30/2026 | 637952805 |